MaxCyte Inc (MXCT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at MaxCyte Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 273.6% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.12 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.10 | – | 9 | -44.50 | -121.90 | -8 | -8 |
| 2025: Q1 | -0.10 | – | 10 | -8.40 | -98.80 | -14 | -15 |
| 2025: Q2 | -0.12 | – | 9 | -18.40 | -145.30 | -10 | -10 |
| 2025: Q3 | -0.12 | – | 7 | -16.40 | -181.80 | -8 | -8 |
| 2025: Q4 | -0.09 | – | 7 | -16.00 | -131.50 | -3 | -3 |
| 2026: Q1 | -0.04 | – | 10 | -7.10 | -49.20 | -8 | -8 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
MaxCyte, Inc., ein Life-Sciences-Unternehmen, entdeckt, entwickelt und vermarktet Zelltherapeutika in den USA und international.
| Employees | 91 |
|---|---|
| Headquarters | Rockville, MD |
| Website | maxcyte.com |
| IPO Date | 30. Jul 2021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Maher Masoud | President, CEO & Executive Director | 1976 |
| Parmeet Ahuja | Chief Financial Officer | 1969 |
| Jay Gelfman | Chief Operations Officer | – |
| Jack Horgan | Senior Vice President of Corporate Development | – |
| Ana-Paula Martins Fernandes | Senior Vice President of Global Sales | – |
| Jill Mayer | Senior Vice President of Human Resources | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.